ABSTRACT
Coronavirus disease-19 (COVID-19) can be a fatal disease and is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). SARS-CoV2 is an enveloped virus that belongs to the Beta coronavirus subfamily. After entering into the target cells, this virus replicates rapidly and leads to cellular damage and uncontrolled pulmonary inflammation. Huge amounts of inflammatory cytokines and chemokines are produced by infected lung cells and are associated with monocyte recruitment and accumulation of inflammatory macrophages at the site of infection. Mitochondrial citrate carrier (CIC) expression increases in these macrophages, which results in elevated levels of cytosolic citrate and the production of inflammatory mediators. In this perspective article, we discuss the role of mitochondrial CIC in the metabolism of inflammatory macrophages and we propose that inhibition of this carrier might be a novel therapeutic approach for COVID-19 patients.